Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Am J Gastroenterol. 2013 Apr;108(4):610-7. doi: 10.1038/ajg.2012.465. Epub 2013 Jan 15.
Although simultaneous occurrences of autoimmune pancreatitis (AIP) and cancer are occasionally observed, it remains largely unknown whether cancer and AIP occur independently or these disorders are interrelated. The aim of this study was to examine the relationship between AIP and cancer.
We conducted a multicenter, retrospective cohort study. One hundred and eight patients who met the Asian diagnostic criteria for AIP were included in the study. We calculated the proportion, standardized incidence ratio (SIR), relative risk, and time course of cancer development in patients with AIP. We also analyzed the clinicopathological characteristics of AIP patients with cancer in comparison with those without cancer.
Of the 108 AIP patients, 18 cancers were found in 15 patients (13.9%) during the median follow-up period of 3.3 years. The SIR of cancer was 2.7 (95% confidence interval (CI) 1.4-3.9), which was stratified into the first year (6.1 (95% CI 2.3-9.9)) and subsequent years (1.5 (95% CI 0.3-2.8)) after AIP diagnosis. Relative risk of cancer among AIP patients at the time of AIP diagnosis was 4.9 (95% CI 1.7-14.9). In six of eight patients whose cancer lesions could be assessed before corticosteroid therapy for AIP, abundant IgG4-positive plasma cell infiltration was observed in the cancer stroma. These six patients experienced no AIP relapse after successful cancer treatment.
Patients with AIP are at high risk of having various cancers. The highest risk for cancer in the first year after AIP diagnosis and absence of AIP relapse after successful treatment of the coexisting cancers suggest that AIP may develop as a paraneoplastic syndrome in some patients.
尽管自身免疫性胰腺炎(AIP)和癌症同时发生的情况偶尔会被观察到,但目前尚不清楚癌症和 AIP 是否独立发生,还是这些疾病之间存在关联。本研究旨在探讨 AIP 与癌症之间的关系。
我们进行了一项多中心、回顾性队列研究。共纳入 108 名符合 AIP 亚洲诊断标准的患者。我们计算了 AIP 患者癌症的比例、标准化发病比(SIR)、相对风险和发病时间。我们还分析了伴有癌症的 AIP 患者与不伴有癌症的 AIP 患者的临床病理特征。
在中位随访 3.3 年期间,108 例 AIP 患者中有 18 例癌症在 15 例患者中被发现(13.9%)。癌症的 SIR 为 2.7(95%可信区间(CI)为 1.4-3.9),分为 AIP 诊断后第 1 年(6.1(95%CI 2.3-9.9))和后续年份(1.5(95%CI 0.3-2.8))。AIP 患者在 AIP 诊断时的癌症相对风险为 4.9(95%CI 1.7-14.9)。在 8 例癌症病变可在 AIP 皮质类固醇治疗前评估的患者中,有 6 例患者的癌症基质中观察到丰富的 IgG4 阳性浆细胞浸润。这 6 例患者在成功治疗并存的癌症后没有出现 AIP 复发。
AIP 患者发生各种癌症的风险较高。AIP 诊断后第 1 年癌症风险最高,且成功治疗并存的癌症后 AIP 无复发,这提示在某些患者中 AIP 可能作为副肿瘤综合征发生。